Topic: Thomson Reuters Corporation
(Reuters) - AstraZeneca went back to court on Wednesday to defend the U.S. patent on its multibillion-dollar cholesterol fighter Crestor in the face of an appeal by generic drugmakers.Industry analysts believe the British company is likely to win the case, protecting exclusivity ...
NEW YORK (Reuters) - Pfizer Inc may have won over shareholders with its recent decision to pare back research and development spending but could be shortchanging them in the long run, according to its former research chief.Pfizer, the world's largest drugmaker, said ...
LONDON (Reuters) - David Livermore is in a race against evolution. In his north London lab, he holds up an evil-smelling culture plate smeared with bacteria. This creamy-yellow growth is the enemy: a new strain of germs resistant to the most powerful ...
SHOHAM, Israel (Reuters) - Teva Pharmaceutical Industries, the world's largest generics drugmaker, said it stands to benefit from the Obama administration's healthcare reform and other plans aimed at getting cheaper medicines to the U.S. market."The healthcare reform and biologics reform are going ...
LONDON (Reuters) - AstraZeneca's revenue fell 4 percent in the third quarter, hit by generic competition to key drugs -- particularly in the United States -- and the absence of last year's windfall sales of swine flu vaccine.AstraZeneca is moving into a ...
LOS ANGELES (Reuters) - Eye care products maker Alcon Inc , which Swiss drugmaker Novartis is buying, reported a 13 percent drop in quarterly profit as merger costs offset sales growth in product areas such as implanted lenses and glaucoma drugs.Alcon posted ...
BOSTON (Reuters) - Genzyme Corp , which is fending off a hostile bid from French drugmaker Sanofi-Aventis SA , said on Wednesday its third-quarter earnings rose as it restored full supply of its biggest-selling drug, Cerezyme, after a manufacturing crisis last year.The ...
NEW YORK (Reuters) - A U.S. judge handed AstraZeneca Plc a huge victory on Tuesday, finding that the patent on its multibillion-dollar cholesterol fighter Crestor is valid, sending the British drugmaker's shares up 9 percent.Judge Joseph Farnan, of the U.S. District Court ...
LONDON (Reuters) - Drugmakers still rely heavily on sales from an aging portfolio of products and the proportion of sales from newer medicines actually fell last year, after a decade of record research spending yielded few new winners.The 2010 Pharmaceutical R&D Factbook, ...
CHICAGO (Reuters) - A third pivotal trial of Amgen Inc's denosumab found that it delayed by 21 percent the risk of fractures and other bone complications in men with advanced prostate cancer compared with current therapy.Amgen filed last month for U.S. Food ...
